Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cipher Pharmaceuticals ( (TSE:CPH) ) has provided an update.
Cipher Pharmaceuticals reported a strong financial performance for the third quarter of 2025, with a 24% increase in total revenue to $12.8 million and a 79% rise in adjusted EBITDA to $7.3 million. The company has made significant progress in reducing its debt, with $32 million in repayments over the past six months, positioning it well for future growth opportunities. The passing of board member Harold M. Wolkin was noted as a loss to the company, given his valuable contributions.
The most recent analyst rating on (TSE:CPH) stock is a Buy with a C$16.50 price target. To see the full list of analyst forecasts on Cipher Pharmaceuticals stock, see the TSE:CPH Stock Forecast page.
Spark’s Take on TSE:CPH Stock
According to Spark, TipRanks’ AI Analyst, TSE:CPH is a Outperform.
Cipher Pharmaceuticals’ strong financial performance and record-breaking earnings in Q2 2025 are significant positives. The company’s strategic initiatives, including debt reduction and share repurchases, further enhance its growth prospects. However, challenges in profitability sustainability and bearish technical indicators moderate the overall outlook.
To see Spark’s full report on TSE:CPH stock, click here.
More about Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on developing and commercializing dermatology products. The company is known for its product portfolio, which includes Natroba™, and it actively seeks growth through acquisitions and licensing opportunities.
Average Trading Volume: 26,347
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$375.6M
For an in-depth examination of CPH stock, go to TipRanks’ Overview page.